248 related articles for article (PubMed ID: 32542461)
1. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.
Nasu S; Suzuki H; Shiroyama T; Tanaka A; Samejima Y; Kanai T; Noda Y; Morishita N; Okamoto N; Hirashima T
Invest New Drugs; 2020 Dec; 38(6):1915-1920. PubMed ID: 32542461
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
Nishima S; Miyanaga A; Saito S; Yuasa M; Takahashi S; Kashiwada T; Sugano T; Noro R; Minegishi Y; Terasaki Y; Saito Y; Kubota K; Seike M; Gemma A
Intern Med; 2021 Feb; 60(4):591-594. PubMed ID: 32999231
[TBL] [Abstract][Full Text] [Related]
4. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Uchida T; Kaira K; Yamaguchi O; Mouri A; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):975-979. PubMed ID: 30864291
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
6. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
7. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
Hayashi H; Yonesaka K; Nakamura A; Fujimoto D; Azuma K; Sakata S; Tachihara M; Ikeda S; Yokoyama T; Hataji O; Yano Y; Hirano K; Daga H; Okada H; Chiba Y; Sakai K; Nishio K; Yamamoto N; Nakagawa K
Lung Cancer; 2022 Jun; 168():38-45. PubMed ID: 35477147
[TBL] [Abstract][Full Text] [Related]
8. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
9. Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Ishii H; Azuma K; Sakai K; Naito Y; Matsuo N; Tokito T; Yamada K; Hoshino T; Nishio K
Sci Rep; 2020 Jan; 10(1):691. PubMed ID: 31959859
[TBL] [Abstract][Full Text] [Related]
10. [Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report].
Gu J; Bai F; Song L; Wang Y
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):804-807. PubMed ID: 34802213
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Kanaji N; Ichihara E; Tanaka T; Ninomiya T; Kozuki T; Ishikawa N; Nishii K; Shoda H; Yamaguchi K; Kawakado K; Toyoda Y; Inoue M; Miyatake N; Watanabe N; Inoue T; Mizoguchi H; Komori Y; Kojima K; Kadowaki N
Lung; 2024 Feb; 202(1):63-72. PubMed ID: 38265672
[TBL] [Abstract][Full Text] [Related]
12. Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
Igawa S; Ono T; Kasajima M; Kusuhara S; Otani S; Fukui T; Yokoba M; Kubota M; Katagiri M; Mitsufuji H; Sasaki J; Naoki K
Invest New Drugs; 2020 Dec; 38(6):1906-1914. PubMed ID: 32415486
[TBL] [Abstract][Full Text] [Related]
13. Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease.
Kiriu T; Tamura D; Tachihara M; Sekiya R; Hazama D; Katsurada M; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Nishimura Y
Intern Med; 2018 Jan; 57(1):91-95. PubMed ID: 29033419
[TBL] [Abstract][Full Text] [Related]
14. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
Yamamoto N; Mera T; Märten A; Hochmair MJ
Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
[TBL] [Abstract][Full Text] [Related]
15. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
[TBL] [Abstract][Full Text] [Related]
16. Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan.
Gemma A; Kusumoto M; Sakai F; Endo M; Kato T; Saito Y; Baba T; Sata M; Yamaguchi O; Yabuki Y; Nogi Y; Jinushi M; Sakamoto K; Sugeno M; Tamura R; Tokimoto T; Ohe Y
J Thorac Oncol; 2020 Dec; 15(12):1893-1906. PubMed ID: 32927121
[TBL] [Abstract][Full Text] [Related]
17. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
18. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
[TBL] [Abstract][Full Text] [Related]
19. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of osimertinib in a Japanese compassionate use program.
Fujiwara Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Sakiyama N; Ando Makihara R; Ohe Y
Jpn J Clin Oncol; 2017 Jul; 47(7):625-629. PubMed ID: 28419328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
